ArticleMelanoma research2026
Prediction of progression of hepatic metastases from uveal melanoma using gadoxetic acid-enhanced magnetic resonance imaging.
Article in Melanoma research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MRI is the preferred method for evaluating hepatic metastases from uveal melanoma. This study was aimed to predict the progression of hepatic metastases from uveal melanoma using gadoxetic acid-enhanced MRI findings. This retrospective study included patients (≥18 years) with uveal melanoma who underwent gadoxetic acid-enhanced liver MRI for evaluation of hepatic metastasis between 2010 and 2023 at two tertiary referral centers. Radiologists retrospectively evaluated the baseline MRI findings of the included patients and assessed tumor responses on follow-up studies according to the Response Evaluation Criteria in Solid Tumors version 1.1. Independent prognostic factors for the time to progression of hepatic metastases were identified using Cox proportional regression analysis. A nomogram based on the multivariable analysis was created and internally validated. A total of 65 patients (mean age, 61.5 ± 14.0 years; 36 men and 29 women) were included. Multivariable analysis revealed that the size of the largest tumor [hazard ratio (HR): 1.028, P = 0.005], precontrast T1 hypointensity (HR: 3.033, P = 0.016), mild to moderate T2 hyperintensity (HR: 3.680, P = 0.001), and hepatobiliary phase hypointensity (HR: 3.370, P = 0.020) were significantly associated with shorter time to progressions of hepatic metastases from uveal melanoma. An internally validated nomogram developed using these MRI findings demonstrated excellent agreement between the predicted probabilities and actual rates of tumor progression, as shown by the calibration plots, with a Harrell's c-index of 0.807. Gadoxetic acid-enhanced MRI findings may be useful in predicting the progression of hepatic metastases from uveal melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.